CN102472753B - 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法 - Google Patents

基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法 Download PDF

Info

Publication number
CN102472753B
CN102472753B CN201080029880.5A CN201080029880A CN102472753B CN 102472753 B CN102472753 B CN 102472753B CN 201080029880 A CN201080029880 A CN 201080029880A CN 102472753 B CN102472753 B CN 102472753B
Authority
CN
China
Prior art keywords
cancer
expression
use according
macroh2a2
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080029880.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102472753A (zh
Inventor
安德里亚·拉杜尔奈尔
朱迪斯·斯珀尔恩
托马斯·穆雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THORAXKLINIK-HEIDELBERG GmbH
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
THORAXKLINIK-HEIDELBERG GmbH
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THORAXKLINIK-HEIDELBERG GmbH, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical THORAXKLINIK-HEIDELBERG GmbH
Publication of CN102472753A publication Critical patent/CN102472753A/zh
Application granted granted Critical
Publication of CN102472753B publication Critical patent/CN102472753B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201080029880.5A 2009-07-02 2010-07-02 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法 Expired - Fee Related CN102472753B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09008679.4 2009-07-02
EP09008679A EP2270510A1 (en) 2009-07-02 2009-07-02 Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
PCT/EP2010/004008 WO2011000573A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Publications (2)

Publication Number Publication Date
CN102472753A CN102472753A (zh) 2012-05-23
CN102472753B true CN102472753B (zh) 2015-02-11

Family

ID=41100520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080029880.5A Expired - Fee Related CN102472753B (zh) 2009-07-02 2010-07-02 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法

Country Status (11)

Country Link
US (1) US20120171225A1 (enExample)
EP (2) EP2270510A1 (enExample)
JP (1) JP5792165B2 (enExample)
CN (1) CN102472753B (enExample)
AU (1) AU2010268389B2 (enExample)
BR (1) BRPI1011925A2 (enExample)
CA (1) CA2766656A1 (enExample)
ES (1) ES2681687T3 (enExample)
SG (1) SG177398A1 (enExample)
WO (1) WO2011000573A1 (enExample)
ZA (1) ZA201109381B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
EP3546944A1 (en) * 2018-03-30 2019-10-02 Universite d'Aix-Marseille (AMU) Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
CN119736252B (zh) * 2025-01-15 2025-06-27 首都医科大学 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013632A1 (en) * 2002-08-01 2004-02-12 Mtm Laboratories Ag Method for solution based diagnosis
CN1688717A (zh) * 2002-08-16 2005-10-26 抗癌公司 实时测量细胞反应

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2474880C (en) * 2002-01-31 2009-11-24 Japan Science And Technology Agency Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
WO2005043163A2 (en) * 2003-11-04 2005-05-12 Roche Diagnostics Gmbh Method for distinguishing who classified aml subtypes
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006119435A2 (en) * 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1948215B1 (en) * 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
US8492328B2 (en) * 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2008292424A (ja) * 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
AU2008294687A1 (en) * 2007-09-07 2009-03-12 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in ER- patients
CA2726531A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013632A1 (en) * 2002-08-01 2004-02-12 Mtm Laboratories Ag Method for solution based diagnosis
CN1688717A (zh) * 2002-08-16 2005-10-26 抗癌公司 实时测量细胞反应

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.;Roepman P. et al.;《Clinical cancer research》;20090101;第15卷(第1期);284-290 *
Developmental and tissue expression patterns of histone macroH2A1 subtypes.;John R.P. et al.;《Journal of cellular biochemistry》;19970430;第65卷(第1期);107-113 *
Developmental changes in histone mcaroH2A1-mediated gene regulation.;Lakshmi N.C. et al.;《Molecular and cellular biology》;20070122;第27卷(第7期);2758-2764 *
The power and the promise of oncogene-induced senescence markers.;Collado M. et al.;《Nature reviews, Cancer》;20060630;第6卷(第6期);472-476 *

Also Published As

Publication number Publication date
AU2010268389A1 (en) 2012-01-19
BRPI1011925A2 (pt) 2017-10-10
ES2681687T3 (es) 2018-09-14
JP5792165B2 (ja) 2015-10-07
WO2011000573A1 (en) 2011-01-06
CN102472753A (zh) 2012-05-23
EP2449383A1 (en) 2012-05-09
US20120171225A1 (en) 2012-07-05
JP2012531612A (ja) 2012-12-10
AU2010268389B2 (en) 2014-09-11
EP2270510A1 (en) 2011-01-05
CA2766656A1 (en) 2011-01-06
ZA201109381B (en) 2012-08-29
EP2449383B1 (en) 2018-05-16
SG177398A1 (en) 2012-02-28
AU2010268389A2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
CN102472753B (zh) 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
Jiang et al. Discovery and clinical application of a novel prostate cancer marker: α-methylacyl CoA racemase (P504S)
Azuma et al. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
Hyeon et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma
CN106662543B (zh) 肺癌患者中的非侵入性基因突变检测
Kinny-Köster et al. Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
Morelli et al. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes
ES2772701T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras de esputo
JP2012524278A (ja) がんの臨床診断および予後診断のためのヒストン修飾パターン
Albarel et al. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012
Liu et al. High FOXM1 expression was associated with bladder carcinogenesis
Zhang et al. Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma
Gong et al. Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma
Nesiu et al. Intracellular chloride ion channel protein-1 expression in clear cell renal cell carcinoma
Zhang et al. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer
Cai et al. High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma
Wang et al. Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer
US20160003848A1 (en) Method for predicting therapy efficacy using nucleosome structure biomarkers
Shimokawa et al. TS expression predicts postoperative recurrence in adenocarcinoma of the lung
Guo et al. Receptors for advanced glycation end products (RAGE) is associated with microvessel density and is a prognostic biomarker for clear cell renal cell carcinoma
Yang et al. Correlation and significance of urinary soluble fas and vascular endothelial growth factor in bladder urothelial cancer
Wang et al. RETRACTED ARTICLE: Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis
Tewari Pancreatic cancer: A challenge to cure
Sasano et al. Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma
Cherciu et al. Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150211

CF01 Termination of patent right due to non-payment of annual fee